title: Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
abstract: Simplified antiretroviral regimens have been developed with the aim of improving treatment adherence and quality of life of HIV-infected patients. The single-class triple-nucleoside reverse transcriptase inhibitor combination has contributed to the improvement of the management of HIV infection, especially in patients with adherence problems and special groups of the patient population. Such a regimen remains an alternative option because of lower virological efficacy compared with the preferred multiclass antiretroviral regimens. However, recently, a nucleoside reverse transcriptase inhibitor abacavir/lamivudine/zidovudine plus tenofovir has been investigated in both antiretroviral-naive patients and in heavily pre-treated patients, as well in the setting of simplification/switching strategies. This experimental combination could be a safe and attractive option that offers the advantages of limited toxicity, few drug interactions and the use of future treatment options with new drugs, especially for patients in later stages of infection.
authors.affiliation: La Sapienza University, Department of Infectious and Tropical Diseases, Polo Pontino (Latina), Viale Regina Elena 331, 00161, Rome, Italy.
authors.forename: Claudio M
authors.initials: CM
authors.lastname: Mastroianni
authors.forename: Gabriella
authors.initials: G
authors.lastname: d'Ettorre
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Vullo
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D063065:Organophosphonates / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000068698:Tenofovir; D015215:Zidovudine / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir